Sign in

    Liana Moussatos

    Research Analyst at Wedbush Securities

    Liana Moussatos's questions to XOMA Royalty (XOMA) leadership

    Liana Moussatos's questions to XOMA Royalty (XOMA) leadership • Q4 2016

    Question

    Liana Moussatos of Wedbush Securities inquired about XOMA's clinical development strategy for its preclinical programs, asking if they would be advanced to proof of concept before out-licensing. She also requested a theoretical example of a future acquisition of a fully-funded program.

    Answer

    CEO Jim Neal explained that while decisions are made case-by-case, the company's intention is to out-license preclinical assets early rather than investing in clinical development. Regarding acquisitions, Neal clarified this is a future strategy, contingent on the company becoming cash-flow positive. The immediate priority is out-licensing XOMA's current proprietary assets.

    Ask Fintool Equity Research AI

    Liana Moussatos's questions to XOMA Royalty (XOMA) leadership • Q2 2015

    Question

    Liana Moussatos of Wedbush Securities asked for an update on the status of several Servier-sponsored trials, including those for diabetic neuropathy, ACS, and Still's disease, and inquired about the future of the non-infectious anterior scleritis trial.

    Answer

    Paul Rubin, SVP of R&D and CMO, stated that the anterior scleritis study is concluding, with no immediate plans for additional trials in that indication. CEO John Varian added that while Servier's other sponsored trials are ongoing, future decisions rest with Servier. He emphasized the strong partnership with Servier, noting they are working collaboratively to determine the best path forward for both companies following the recent gevokizumab data.

    Ask Fintool Equity Research AI